T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections.

By Daniel T. Utzschneider, M. Charmoy, Vijaykumar Chennupati, Laurène Pousse, D. Ferreira, Sandra P. Calderon-Copete, M. Danilo, Francesca Alfei, M. Hofmann, D. Wieland and 4 more. Immunity, 2016

978 citations recorded by the source corpus.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/62621a2a74a7493f3e8c381644561d8f82e85b99

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

Citations in the corpus

DE NOVO EPIGENETIC PROGRAMS INHIBIT PD-1 BLOCKADE-MEDIATED T-CELL REJUVENATION (2017, positive): “Recent studies have also linked Tcf7 expression to retention of T cell function during chronic infection (Im et al., 2016; Utzschneider et al., 2016).”
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. (2019, methodology): “However, longer exposure to chronic infection results in irreversible commitment to exhaustion (89, 135, 136).”
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. (2019, positive): “In addition to EOMES and TBET, the transcription factor TCF1 (T cell-specific transcription factor 1) has been proposed as a predictive marker of response to antiPD-1 therapy (Utzschneider et al., 2016).”
Mechanisms of resistance to immune checkpoint inhibitors (2018, background): “…in response to PD-1/PD-L1 blockade identified a unique subset of CD8þPD-1þ T cells that share features of T-follicular helper cells, CD8 memory precursors, and stem cells (Im et al, 2016), and resemble CXCR5þ CD8þ follicular T cells (He et al, 2016; Leong et al, 2016; Utzschneider et al, 2016).”
Pan-cancer single-cell landscape of tumor-infiltrating T cells (2021, background): “It has been hypothesized that the progenitor cells that express CXCR5 or TCF7 give rise to terminal Tex cells (23, 32, 33).”
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade (2016, neutral): “In particular, the TEX population appears heterogeneous in TCIR expression, exhaustion-related markers, and reinvigoration potential (Blackburn et al., 2008; He et al., 2016; Im et al., 2016; Utzschneider et al., 2016).”
Acquired Resistance to Immune Checkpoint Inhibitors (2020, background): “…and shown to reinvigorate and sustain effective immunity of CD8+ T cells against chronic lymphocytic choriomeningitis mouse virus (LCMV) infection upon anti-PD-1 treatment (Blank et al., 2019; Chen et al., 2019b; Hudson et al., 2019; Im et al., 2016; Utzschneider et al., 2016; Zhou et al., 2010).”
Defining T cell states associated with response to checkpoint immunotherapy in melanoma (2018, positive): “…November 1, 2018 self-renewal, and persistence of memory CD8+ T cells (Zhou et al., 2010) and reinvigoration and effective immunity of CD8+ T cells against chronic lymphocytic choriomeningitis mouse virus (LCMV) infection upon anti-PD-1 treatment (Im et al., 2016; Utzschneider et al., 2016).”